Alnylam Pharmaceuticals (ALNY) Tops Q2 EPS by 3c
Tweet
Share
E-mailGet Alerts ALNY Hot Sheet
Join SI Premium – FREE
Alnylam Pharmaceuticals (NASDAQ: ALNY) reported Q2 EPS of ($0.33), $0.03 better than the analyst estimate of ($0.36). Revenue for the quarter came in at $20.6 million versus the consensus estimate of $19.97 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Alnylam Pharmaceuticals (ALNY) PT Lowered to $256 at Wells Fargo
- CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance
- HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
